$HBIO
HARVARD BIOSCIENCE INC

2012 Q2 Form 10-Q Financial Statement

#000119312512346339 Filed on August 09, 2012

View on sec.gov

Income Statement

Concept 2012 Q2 2011 Q2
Revenue $28.50M $27.14M
YoY Change 4.98% 4.78%
Cost Of Revenue $14.90M $14.36M
YoY Change 3.78% 3.63%
Gross Profit $13.60M $12.79M
YoY Change 6.34% 6.1%
Gross Profit Margin 47.71% 47.1%
Selling, General & Admin $9.645M $8.477M
YoY Change 13.78% 5.99%
% of Gross Profit 70.95% 66.3%
Research & Development $1.972M $1.128M
YoY Change 74.82% 2.36%
% of Gross Profit 14.51% 8.82%
Depreciation & Amortization $1.050M $1.100M
YoY Change -4.55% 14.58%
% of Gross Profit 7.72% 8.6%
Operating Expenses $11.12M $10.27M
YoY Change 8.33% 6.08%
Operating Profit $2.474M $2.519M
YoY Change -1.79% 6.2%
Interest Expense $152.0K $192.0K
YoY Change -20.83% 48.84%
% of Operating Profit 6.14% 7.62%
Other Income/Expense, Net -$226.0K -$519.0K
YoY Change -56.45% -515.2%
Pretax Income $2.248M $2.000M
YoY Change 12.4% -19.9%
Income Tax $698.0K $630.0K
% Of Pretax Income 31.05% 31.5%
Net Earnings $774.0K $1.370M
YoY Change -43.5% -27.21%
Net Earnings / Revenue 2.72% 5.05%
Basic Earnings Per Share $0.02 $0.05
Diluted Earnings Per Share $0.02 $0.05
COMMON SHARES
Basic Shares Outstanding 28.77M shares 28.43M shares
Diluted Shares Outstanding 29.60M shares 30.19M shares

Balance Sheet

Concept 2012 Q2 2011 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.70M $21.70M
YoY Change -13.82% 38.22%
Cash & Equivalents $18.66M $21.75M
Short-Term Investments
Other Short-Term Assets $2.907M $2.448M
YoY Change 18.75% 308.0%
Inventory $17.75M $19.01M
Prepaid Expenses
Receivables $15.07M $14.46M
Other Receivables $2.900M $2.400M
Total Short-Term Assets $58.30M $62.88M
YoY Change -7.28% 33.22%
LONG-TERM ASSETS
Property, Plant & Equipment $3.778M $3.438M
YoY Change 9.89% 7.44%
Goodwill $35.37M $34.07M
YoY Change 3.83%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $110.0K $286.0K
YoY Change -61.54% -64.25%
Total Long-Term Assets $71.23M $66.13M
YoY Change 7.71% 18.73%
TOTAL ASSETS
Total Short-Term Assets $58.30M $62.88M
Total Long-Term Assets $71.23M $66.13M
Total Assets $129.5M $129.0M
YoY Change 0.4% 25.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.607M $5.367M
YoY Change -14.16% 9.53%
Accrued Expenses $3.089M $3.646M
YoY Change -15.28% 13.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.913M $10.34M
YoY Change -4.17% 1.41%
LONG-TERM LIABILITIES
Long-Term Debt $16.10M $17.11M
YoY Change -5.89% 52.74%
Other Long-Term Liabilities $4.800M $3.700M
YoY Change 29.73% -5.13%
Total Long-Term Liabilities $16.10M $17.11M
YoY Change -5.89% 13.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.913M $10.34M
Total Long-Term Liabilities $16.10M $17.11M
Total Liabilities $31.52M $32.20M
YoY Change -2.13% 17.52%
SHAREHOLDERS EQUITY
Retained Earnings -$78.33M -$80.40M
YoY Change -2.57%
Common Stock $193.2M $189.6M
YoY Change 1.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares 7.746M shares 7.746M shares
Shareholders Equity $98.02M $96.81M
YoY Change
Total Liabilities & Shareholders Equity $129.5M $129.0M
YoY Change 0.4% 25.37%

Cashflow Statement

Concept 2012 Q2 2011 Q2
OPERATING ACTIVITIES
Net Income $774.0K $1.370M
YoY Change -43.5% -27.21%
Depreciation, Depletion And Amortization $1.050M $1.100M
YoY Change -4.55% 14.58%
Cash From Operating Activities $2.540M $1.660M
YoY Change 53.01% -46.1%
INVESTING ACTIVITIES
Capital Expenditures -$310.0K -$440.0K
YoY Change -29.55% 62.96%
Acquisitions
YoY Change
Other Investing Activities -$480.0K $0.00
YoY Change -100.0%
Cash From Investing Activities -$800.0K -$440.0K
YoY Change 81.82% -74.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -570.0K 330.0K
YoY Change -272.73% -114.86%
NET CHANGE
Cash From Operating Activities 2.540M 1.660M
Cash From Investing Activities -800.0K -440.0K
Cash From Financing Activities -570.0K 330.0K
Net Change In Cash 1.170M 1.550M
YoY Change -24.52% -278.16%
FREE CASH FLOW
Cash From Operating Activities $2.540M $1.660M
Capital Expenditures -$310.0K -$440.0K
Free Cash Flow $2.850M $2.100M
YoY Change 35.71% -37.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-12
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Voluntary Filers
EntityVoluntaryFilers
No
dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2012Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28793267 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001123494
dei Entity Registrant Name
EntityRegistrantName
HARVARD BIOSCIENCE INC
dei Document Period End Date
DocumentPeriodEndDate
2012-06-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18655000 USD
CY2012Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15066000 USD
CY2012Q2 us-gaap Inventory Net
InventoryNet
17746000 USD
CY2012Q2 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
3929000 USD
CY2012Q2 us-gaap Other Assets Current
OtherAssetsCurrent
2907000 USD
CY2012Q2 us-gaap Assets Current
AssetsCurrent
58303000 USD
CY2012Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3778000 USD
CY2012Q2 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
8231000 USD
CY2012Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
22479000 USD
CY2012Q2 us-gaap Goodwill
Goodwill
35369000 USD
CY2012Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1261000 USD
CY2012Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
110000 USD
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2012Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
320000 USD
CY2012Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3089000 USD
CY2012Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1327000 USD
CY2012Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9913000 USD
CY2012Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16100000 USD
CY2012Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
684000 USD
CY2012Q2 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
4819000 USD
CY2012Q2 us-gaap Liabilities
Liabilities
31516000 USD
CY2012Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2012Q2 us-gaap Assets
Assets
129531000 USD
CY2012Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4607000 USD
CY2012Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
570000 USD
CY2012Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
192828000 USD
CY2012Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-78331000 USD
CY2012Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6178000 USD
CY2012Q2 us-gaap Treasury Stock Carrying Basis
TreasuryStockCarryingBasis
10668000 USD
CY2012Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
129531000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17916000 USD
CY2011Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15078000 USD
CY2011Q4 us-gaap Inventory Net
InventoryNet
18160000 USD
CY2011Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
3908000 USD
CY2011Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2501000 USD
CY2011Q4 us-gaap Assets Current
AssetsCurrent
57563000 USD
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3086000 USD
CY2011Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
7925000 USD
CY2011Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
22367000 USD
CY2011Q4 us-gaap Goodwill
Goodwill
34209000 USD
CY2011Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1269000 USD
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
215000 USD
CY2011Q4 us-gaap Assets
Assets
126634000 USD
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4959000 USD
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
483000 USD
CY2011Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
251000 USD
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3323000 USD
CY2011Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
543000 USD
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9559000 USD
CY2011Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16300000 USD
CY2011Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
369000 USD
CY2011Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
4907000 USD
CY2011Q4 us-gaap Liabilities
Liabilities
31135000 USD
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2011Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
191157000 USD
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79630000 USD
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5722000 USD
CY2011Q4 us-gaap Treasury Stock Carrying Basis
TreasuryStockCarryingBasis
10668000 USD
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
126634000 USD
CY2011Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
302000 USD
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36289170 shares
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28543663 shares
CY2011Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
7745507 shares
CY2012Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
314000 USD
CY2012Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2012Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36538774 shares
CY2012Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28793267 shares
CY2012Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
7745507 shares
CY2012Q2 us-gaap Common Stock Value
CommonStockValue
364000 USD
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
362000 USD
CY2012Q2 us-gaap Stockholders Equity
StockholdersEquity
98015000 USD
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
95499000 USD
CY2011Q4 us-gaap Line Of Credit Facility Amount Outstanding
LineOfCreditFacilityAmountOutstanding
16300000 USD
CY2012Q2 us-gaap Line Of Credit Facility Amount Outstanding
LineOfCreditFacilityAmountOutstanding
16100000 USD
CY2012Q2 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
3900000 USD
CY2012Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 USD
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 USD
us-gaap Revenues
Revenues
56818000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
29803000 USD
us-gaap Gross Profit
GrossProfit
27015000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9512000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9760000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3689000 USD
us-gaap Restructuring Charges
RestructuringCharges
137000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1391000 USD
us-gaap Operating Expenses
OperatingExpenses
24489000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
2526000 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-57000 USD
us-gaap Interest Expense
InterestExpense
300000 USD
us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
26000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-281000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-612000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1914000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
615000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
CY2012Q2 us-gaap Revenues
Revenues
28496000 USD
CY2012Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14881000 USD
CY2012Q2 us-gaap Gross Profit
GrossProfit
13615000 USD
CY2012Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4743000 USD
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4902000 USD
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1972000 USD
CY2012Q2 us-gaap Restructuring Charges
RestructuringCharges
-13000 USD
CY2012Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
712000 USD
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
12316000 USD
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1299000 USD
CY2012Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-16000 USD
CY2012Q2 us-gaap Interest Expense
InterestExpense
152000 USD
CY2012Q2 us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
12000 USD
CY2011Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1128000 USD
CY2011Q2 us-gaap Restructuring Charges
RestructuringCharges
-28000 USD
CY2011Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
689000 USD
CY2011Q2 us-gaap Operating Expenses
OperatingExpenses
10266000 USD
CY2012Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-70000 USD
CY2012Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-226000 USD
CY2012Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1073000 USD
CY2012Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
299000 USD
CY2012Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2012Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2011Q2 us-gaap Revenues
Revenues
27143000 USD
CY2011Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14358000 USD
CY2011Q2 us-gaap Gross Profit
GrossProfit
12785000 USD
CY2011Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4271000 USD
CY2011Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4206000 USD
CY2011Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
2519000 USD
CY2011Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-11000 USD
CY2011Q2 us-gaap Interest Expense
InterestExpense
192000 USD
CY2011Q2 us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
16000 USD
CY2011Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-332000 USD
CY2011Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-519000 USD
CY2011Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2000000 USD
CY2011Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
630000 USD
CY2011Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2011Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
28301000 USD
us-gaap Revenues
Revenues
53456000 USD
us-gaap Gross Profit
GrossProfit
25155000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8449000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8561000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2395000 USD
us-gaap Restructuring Charges
RestructuringCharges
-28000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1310000 USD
us-gaap Operating Expenses
OperatingExpenses
20687000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
4468000 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-33000 USD
us-gaap Interest Expense
InterestExpense
386000 USD
us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
31000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-406000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-794000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
3674000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
629000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
774000 USD
CY2011Q2 us-gaap Net Income Loss
NetIncomeLoss
1370000 USD
us-gaap Net Income Loss
NetIncomeLoss
1299000 USD
us-gaap Net Income Loss
NetIncomeLoss
3045000 USD
CY2012Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-1718000 USD
CY2011Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
317000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-456000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
2172000 USD
CY2012Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-944000 USD
CY2011Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1687000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
843000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
5217000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1415000 USD
us-gaap Depreciation
Depreciation
622000 USD
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
2000 USD
hbio Amortization Of Catalog Costs
AmortizationOfCatalogCosts
106000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-6000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
44000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-321000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-211000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-806000 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
196000 USD
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-657000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-22000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-218000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
54000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-360000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4153000 USD
us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
-610000 USD
hbio Additions To Catalog Costs
AdditionsToCatalogCosts
0 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
2863000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3470000 USD
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
500000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
701000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
402000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-145000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
739000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
201000 USD
us-gaap Interest Paid
InterestPaid
276000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1210000 USD
us-gaap Depreciation
Depreciation
638000 USD
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
15000 USD
hbio Amortization Of Catalog Costs
AmortizationOfCatalogCosts
145000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
15000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
44000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
233000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1289000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2812000 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
217000 USD
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
299000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-62000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1614000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
41000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-726000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2795000 USD
us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
-866000 USD
hbio Additions To Catalog Costs
AdditionsToCatalogCosts
-140000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
1267000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
18000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-988000 USD
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
0 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
900000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
327000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-573000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
809000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2043000 USD
CY2011Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21747000 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19704000 USD
us-gaap Interest Paid
InterestPaid
310000 USD
hbio Non Cash Restructuring Charge
NonCashRestructuringCharge
-13000 USD
hbio Non Cash Restructuring Charge
NonCashRestructuringCharge
-28000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
933000 USD
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<p style='margin-top:13.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:-0.0500000000000007px;">2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Recently Issued Accounting Pronouncements </font></p><p style='margin-top:0pt; margin-bottom:0pt'>&#160;</p><p style='margin-top:0pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:24.5px;">In </font><font style="font-family:Times New Roman;font-size:10pt;">July 2012</font><font style="font-family:Times New Roman;font-size:10pt;">, the FASB issued Accounting Standards Update No.&#160;201</font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;">-0</font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Intangibles- Goodwill and Other</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">- Testing Indefinite-Lived Intangible Assets for Impairment</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"> (ASU 201</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">2</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">-</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">0</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">2</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">)</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">Under the amendments in this </font><font style="font-family:Times New Roman;font-size:10pt;">u</font><font style="font-family:Times New Roman;font-size:10pt;">pdate, </font><font style="font-family:Times New Roman;font-size:10pt;">the </font><font style="font-family:Times New Roman;font-size:10pt;">Company</font><font style="font-family:Times New Roman;font-size:10pt;"> has the option </font><font style="font-family:Times New Roman;font-size:10pt;">first </font><font style="font-family:Times New Roman;font-size:10pt;">to </font><font style="font-family:Times New Roman;font-size:10pt;">assess qualitative factors to determine </font><font style="font-family:Times New Roman;font-size:10pt;">whether the existence of events or circumstances</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">leads to a</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">determination that it is more likely than not that the </font><font style="font-family:Times New Roman;font-size:10pt;">indefinite-lived intangible asset is impaired</font><font style="font-family:Times New Roman;font-size:10pt;">. If, after assessing the totality of</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">events or circumstances, </font><font style="font-family:Times New Roman;font-size:10pt;">the Company</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">concludes that</font><font style="font-family:Times New Roman;font-size:10pt;"> it is not more likely than not that</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">the </font><font style="font-family:Times New Roman;font-size:10pt;">indefinite-lived intangible asset is impaired, </font><font style="font-family:Times New Roman;font-size:10pt;">then </font><font style="font-family:Times New Roman;font-size:10pt;">the </font><font style="font-family:Times New Roman;font-size:10pt;">Company</font><font style="font-family:Times New Roman;font-size:10pt;"> is not required to take further action</font><font style="font-family:Times New Roman;font-size:10pt;">. However, if </font><font style="font-family:Times New Roman;font-size:10pt;">the Company </font><font style="font-family:Times New Roman;font-size:10pt;">concludes</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">otherwise, then it is required to </font><font style="font-family:Times New Roman;font-size:10pt;">determine the </font><font style="font-family:Times New Roman;font-size:10pt;">fair value of the</font><font style="font-family:Times New Roman;font-size:10pt;"> indefinite-lived intangible asset</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">and perform the quantitative impairment test by</font><font style="font-family:Times New Roman;font-size:10pt;"> comparing the fair value</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">with the carrying amount</font><font style="font-family:Times New Roman;font-size:10pt;"> in accordance with subtopic </font><font style="font-family:Times New Roman;font-size:10pt;">350-</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;">0. Under the amendments in this </font><font style="font-family:Times New Roman;font-size:10pt;">u</font><font style="font-family:Times New Roman;font-size:10pt;">pdate, </font><font style="font-family:Times New Roman;font-size:10pt;">the Company</font><font style="font-family:Times New Roman;font-size:10pt;"> has the option to</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">bypass the qualitative assessment for any </font><font style="font-family:Times New Roman;font-size:10pt;">indefinite-lived intangible asset</font><font style="font-family:Times New Roman;font-size:10pt;"> in any period and</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">proceed directly to performing the </font><font style="font-family:Times New Roman;font-size:10pt;">quantitative impairment test</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">The Company </font><font style="font-family:Times New Roman;font-size:10pt;">may resume performing the qualitative assessment in any</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">subsequent period</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">The provisions of this update will be effective for </font><font style="font-family:Times New Roman;font-size:10pt;">the Company </font><font style="font-family:Times New Roman;font-size:10pt;">in fiscal years beginning after </font><font style="font-family:Times New Roman;font-size:10pt;">September</font><font style="font-family:Times New Roman;font-size:10pt;">&#160;15, 201</font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;">, and for the interim periods within fiscal years with early adoption permitted. </font><font style="font-family:Times New Roman;font-size:10pt;">The Company</font><font style="font-family:Times New Roman;font-size:10pt;"> believe</font><font style="font-family:Times New Roman;font-size:10pt;">s</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">the </font><font style="font-family:Times New Roman;font-size:10pt;">adoption of this new guidance will not have a material impact on </font><font style="font-family:Times New Roman;font-size:10pt;">its</font><font style="font-family:Times New Roman;font-size:10pt;"> consolidated results of operations or financial position.</font></p>
CY2012Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
40719000 USD
CY2012Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
18240000 USD
CY2011Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
16884000 USD
CY2011Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
39251000 USD
CY2012Q2 hbio Total Indefinite Lived Intangible Assets Including Goodwill
TotalIndefiniteLivedIntangibleAssetsIncludingGoodwill
36630000 USD
CY2012Q2 hbio Total Intangible Assets
TotalIntangibleAssets
77349000 USD
CY2011Q4 hbio Total Indefinite Lived Intangible Assets Including Goodwill
TotalIndefiniteLivedIntangibleAssetsIncludingGoodwill
35478000 USD
CY2011Q4 hbio Total Intangible Assets
TotalIntangibleAssets
74729000 USD
us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
267000 USD
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
1232000 USD
us-gaap Goodwill Translation Adjustments
GoodwillTranslationAdjustments
72000 USD
us-gaap Future Amortization Expense Year One
FutureAmortizationExpenseYearOne
2800000 USD
us-gaap Future Amortization Expense Year Two
FutureAmortizationExpenseYearTwo
2600000 USD
us-gaap Future Amortization Expense Year Three
FutureAmortizationExpenseYearThree
2400000 USD
us-gaap Future Amortization Expense Year Four
FutureAmortizationExpenseYearFour
2100000 USD
us-gaap Future Amortization Expense Year Five
FutureAmortizationExpenseYearFive
2000000 USD
CY2012Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8198000 USD
CY2012Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
805000 USD
CY2012Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
8743000 USD
CY2011Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8372000 USD
CY2011Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
626000 USD
CY2011Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
9162000 USD
CY2012Q2 hbio Business Acquisition Direct Acquisition Costs In Income Statement
BusinessAcquisitionDirectAcquisitionCostsInIncomeStatement
100000 USD
hbio Business Acquisition Direct Acquisition Costs In Income Statement
BusinessAcquisitionDirectAcquisitionCostsInIncomeStatement
300000 USD
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
539450 shares
CY2010Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
158000 USD
CY2011 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
-58000 USD
CY2011 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
44000 USD
CY2011Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
144000 USD
us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
-57000 USD
us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
86000 USD
CY2012Q2 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
173000 USD
CY2012Q2 us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
73000 USD
CY2012Q2 us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
188000 USD
CY2012Q2 us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
131000 USD
CY2012Q2 us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
-49000 USD
CY2012Q2 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
179000 USD
CY2011Q2 us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
56000 USD
CY2011Q2 us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
211000 USD
CY2011Q2 us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
157000 USD
CY2011Q2 us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
-36000 USD
CY2011Q2 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
146000 USD
us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
158000 USD
us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
386000 USD
us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
-100000 USD
us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
377000 USD
us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
112000 USD
us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
424000 USD
us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
315000 USD
us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
-72000 USD
us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
293000 USD
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
400000 USD
CY2012Q2 us-gaap Defined Benefit Plan Estimated Future Employer Contributions In Current Fiscal Year
DefinedBenefitPlanEstimatedFutureEmployerContributionsInCurrentFiscalYear
400000 USD
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
400000 USD
CY2012Q2 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
200000 USD
CY2011Q2 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
200000 USD
hbio Estimated Rental Expenses Current Year
EstimatedRentalExpensesCurrentYear
1200000 USD
CY2012Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1047000 USD
CY2012Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1005000 USD
CY2012Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
890000 USD
CY2012Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
679000 USD
CY2012Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
418000 USD
CY2012Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
130000 USD
CY2012Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
4169000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
600000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
800000 USD
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2700645 shares
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8519575 shares
CY2011Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
4.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1210934 shares
hbio Stock Options And Restricted Stock Units Issued
StockOptionsAndRestrictedStockUnitsIssued
1560229 shares
hbio Fungible Share Adjustment For Restricted Stock Units Granted
FungibleShareAdjustmentForRestrictedStockUnitsGranted
-275943 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
-97500 shares
us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
45912 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
-6.58
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8720509 shares
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1881456 shares
CY2012Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
4.19
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.09
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
677193 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
349295 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
-164090 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.57
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.32
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.97
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.59
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
-912500 shares
hbio Stock Options And Restricted Stock Units Cancelled
StockOptionsAndRestrictedStockUnitsCancelled
959962 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
-47462 shares
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue
4.21
hbio Fungible Share Adjustment For Restricted Stock Units Cancelled
FungibleShareAdjustmentForRestrictedStockUnitsCancelled
11109 shares
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5507
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0078
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm
5.98
CY2011Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5424
CY2011Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0201
CY2011Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2011Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm
5.94
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5509
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0080
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm
5.98
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5424
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0201
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm
5.94
CY2012Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
827463 shares
CY2012Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29595249 shares
CY2011Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28428019 shares
CY2011Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1759223 shares
CY2012Q2 us-gaap Share Based Compensation
ShareBasedCompensation
718000 USD
CY2011Q2 us-gaap Share Based Compensation
ShareBasedCompensation
658000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1415000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1210000 USD
CY2012Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28767786 shares
CY2011Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30187242 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28738772 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
895016 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29633788 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28408437 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1435509 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29843946 shares
CY2012Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4466845 shares
CY2011Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2332780 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4399239 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2964255 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
0.85
CY2012Q2 hbio Employee Stock Purchase Plan Shares Authorized
EmployeeStockPurchasePlanSharesAuthorized
500000 shares
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
25597 shares
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
22587 shares
CY2012Q2 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0 shares
CY2011Q2 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.84
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0 USD
CY2012Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0 USD
CY2011Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0 USD
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
435972 shares
us-gaap Deferred Compensation Arrangement With Individual Maximum Contractual Term
DeferredCompensationArrangementWithIndividualMaximumContractualTerm
10 years
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximum
4 years
CY2012Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
20000000 USD
CY2012Q2 hbio Lender Approval To Fund Acquisition With Cash Promissory Note In Excess Of Threshold
LenderApprovalToFundAcquisitionWithCashPromissoryNoteInExcessOfThreshold
6000000 USD
CY2012Q2 hbio Lender Approval To Fund Acquisition With Equity In Excess Of Threshold
LenderApprovalToFundAcquisitionWithEquityInExcessOfThreshold
10000000 USD
hbio Interest Rate In Excess Of Libor On Credit Facility
InterestRateInExcessOfLiborOnCreditFacility
0.0300
CY2012Q2 us-gaap Line Of Credit Facility Interest Rate At Period End
LineOfCreditFacilityInterestRateAtPeriodEnd
0.0325
CY2012Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.2790
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.3210
CY2010Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
700000 USD
CY2011 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
500000 USD
CY2011Q2 us-gaap Assets
Assets
129010000 USD
CY2012Q2 us-gaap Revenues From Transactions With Other Operating Segments Of Same Entity
RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity
0 USD
CY2011Q2 us-gaap Revenues From Transactions With Other Operating Segments Of Same Entity
RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity
0 USD
us-gaap Revenues From Transactions With Other Operating Segments Of Same Entity
RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity
0 USD
us-gaap Revenues From Transactions With Other Operating Segments Of Same Entity
RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity
0 USD
CY2012Q2 us-gaap Business Acquisition Cost Of Acquired Entity Cash Paid
BusinessAcquisitionCostOfAcquiredEntityCashPaid
2863000 USD
CY2011Q2 us-gaap Business Acquisition Cost Of Acquired Entity Cash Paid
BusinessAcquisitionCostOfAcquiredEntityCashPaid
0 USD
CY2012Q2 hbio Business Acquisition Total Intangible Assets Amount Including Goodwill
BusinessAcquisitionTotalIntangibleAssetsAmountIncludingGoodwill
2416000 USD
CY2011Q2 hbio Business Acquisition Total Intangible Assets Amount Including Goodwill
BusinessAcquisitionTotalIntangibleAssetsAmountIncludingGoodwill
0 USD
CY2012Q2 us-gaap Business Acquisition Purchase Price Allocation Net Tangible Assets
BusinessAcquisitionPurchasePriceAllocationNetTangibleAssets
97000 USD
CY2012Q2 us-gaap Business Acquisition Contingent Consideration At Fair Value
BusinessAcquisitionContingentConsiderationAtFairValue
20000 USD
CY2012Q2 hbio Acquisition Of Intellectual Property
AcquisitionOfIntellectualProperty
370000 USD
CY2011Q2 us-gaap Business Acquisition Purchase Price Allocation Net Tangible Assets
BusinessAcquisitionPurchasePriceAllocationNetTangibleAssets
0 USD
CY2011Q2 us-gaap Business Acquisition Contingent Consideration At Fair Value
BusinessAcquisitionContingentConsiderationAtFairValue
0 USD
CY2011Q2 hbio Acquisition Of Intellectual Property
AcquisitionOfIntellectualProperty
0 USD

Files In Submission

Name View Source Status
0001193125-12-346339-index-headers.html Edgar Link pending
0001193125-12-346339-index.html Edgar Link pending
0001193125-12-346339.txt Edgar Link pending
0001193125-12-346339-xbrl.zip Edgar Link pending
d384277d10q.htm Edgar Link pending
d384277dex311.htm Edgar Link pending
d384277dex312.htm Edgar Link pending
d384277dex321.htm Edgar Link pending
d384277dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
hbio-20120630.xml Edgar Link completed
hbio-20120630.xsd Edgar Link pending
hbio-20120630_cal.xml Edgar Link unprocessable
hbio-20120630_def.xml Edgar Link unprocessable
hbio-20120630_lab.xml Edgar Link unprocessable
hbio-20120630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending